思春期から成人期への移行:てんかん移行期集団における気分障害
Sarita Maturu1, Yevgeniya Gokun1, Richelle Collins2
1Neurology Department, The Ohio State University, Columbus OH, Ohio, USA.
Epileptic disorders : international epilepsy journal with videotape
|February 27, 2026
まとめ
てんかんのある思春期および若年成人には、気分障害の高い有病率が見られます。女性、20歳以上、および複数の抗てんかん薬を服用している患者は、リスクが高くなります。
科学分野:
- 神経学
- 精神医学
- 思春期医学
背景:
- てんかんのある思春期および若年成人(AYA)は、自己管理に苦労することが多く、健康状態や社会的な転帰が悪くなる可能性があります。
- AYAてんかん患者の根底にある気分障害は、ケアの移行を複雑にする可能性がありますが、その有病率と危険因子に関するデータは限られています。
研究 の 目的:
- AYAてんかん患者における不安とうつ病の有病率を決定すること。
- 2つの学術センターにおけるこの集団における気分障害に関連する危険因子を特定すること。
主な方法:
- 2つの三次ケアセンターから217人のAYAてんかん患者(16〜26歳)が登録されました。
- 患者はてんかん移行期準備評価質問票(EPI-TRAQ)を完了しました。
- ロジスティック回帰により、気分障害と、年齢、性別、抗てんかん薬(ASM)の使用などの要因との関連を分析しました。
主要な成果:
- 28%のAYAてんかん患者が気分障害と診断されました。
- 女性は男性と比較して気分障害のオッズが2.2倍高かった。
- 高齢(20歳以上)および2つ以上のASMの使用は、気分障害のオッズの増加と関連していました。
結論:
- AYAてんかん患者における気分障害の監視強化が不可欠です。
- 特定された主な危険因子には、女性、20歳以上、および複数のASMの使用が含まれます。
- リスクの高い個人に対しては、早期介入とターゲットを絞ったサポートが推奨されます。
関連する概念動画
Epilepsy and Seizures: Overview
1.5K
Epilepsy is a chronic neurological disease marked by recurrent, unpredictable seizures. These seizures are caused by abnormal electrical discharges in the brain, leading to behavior, sensation, or consciousness alterations. They can also cause transient impairment of awareness, interfering with daily activities.
Various factors can trigger epilepsy, including genetic factors, brain damage, metabolic causes, and unknown etiology. Diagnosis of epilepsy involves electroencephalography (EEG), which...
Various factors can trigger epilepsy, including genetic factors, brain damage, metabolic causes, and unknown etiology. Diagnosis of epilepsy involves electroencephalography (EEG), which...
1.5K
Mania and Antimanic Drugs: Overview
708
Mania, a psychological condition characterized by elevated mood, increased energy, and reduced sleep need, is part of the bipolar disorder cycle. The exact cause of mania isn't entirely known, but it is thought to be a combination of genetic, environmental, and neurological factors. Bipolar disorder involves alternating manic and depressive episodes. Mood stabilizers like lithium, antipsychotics, and anticonvulsants help manage these episodes. Lithium carbonate is particularly effective as...
708
Electroconvulsive Therapy
1.5K
Electroconvulsive therapy (ECT), or shock therapy, remains a critical biomedical intervention for severe, treatment-resistant depression. While its origins can be traced back to Hippocrates' observations that malaria-induced convulsions alleviated mental illness, modern ECT has evolved significantly from its earlier, more primitive applications. First introduced in 1938 by Ugo Cerletti and his colleagues, ECT involves inducing controlled seizures using electrical currents. In its early...
1.5K
Antiepileptic Drugs: Potassium Channel Activators
864
Ezocgabine or retigabine, an antiepileptic drug of remarkable efficacy, has revolutionized the management of seizures. It is a potassium channel activator, explicitly targeting the family of Q subtype potassium channels. It enhances the transmembrane potassium currents, regulating neuronal excitability. This action stabilizes the resting membrane potential, a pivotal factor in mitigating the hyperexcitability that characterizes epilepsy.
Ezogabine has gained approval as an adjunctive treatment...
Ezogabine has gained approval as an adjunctive treatment...
864
Bipolar Disorder
1.2K
Bipolar disorder is a chronic mental health condition marked by significant mood fluctuations, including episodes of mania and depression. Elevated energy levels, heightened mood or irritability, impulsive behavior, reduced sleep needs, rapid speech, racing thoughts, inflated self-esteem, and distractibility characterize mania. Individuals with bipolar disorder often alternate between depressive and manic states, with periods of emotional stability lasting an average of six months to a year.
1.2K
Antiepileptic Drugs: GABAergic Pathway Potentiators
1.5K
γ-aminobutyric acid or GABA, plays a pivotal role as an inhibitory neurotransmitter in the brain. GABA pathway potentiators, also known as GABAergic drugs, are a class of pharmaceutical agents designed to enhance the functioning of the GABAergic system. These medications primarily treat epilepsy, a neurological disorder characterized by recurrent seizures.
The key GABA pathway potentiators used in epilepsy management are as follows.
Benzodiazepines are a well-known class of drugs used for...
The key GABA pathway potentiators used in epilepsy management are as follows.
Benzodiazepines are a well-known class of drugs used for...
1.5K


